<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Clinical</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?</title>
      <description>
        <![CDATA[Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by competitor Sanofi SA, which said that the phase III Mobilize study testing riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) will be stopped for futility.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731720</guid>
      <pubDate>Wed, 10 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731720-sanofi-phase-iii-cidp-quit-dents-dianthus-c1-mismatch</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-nerve-cell-pain.webp?t=1682600134" type="image/jpeg" medium="image" fileSize="413083">
        <media:title type="plain">3D illustration of a nerve cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent submits NDA for CLDN18.2 ADC for gastric cancer</title>
      <description>
        <![CDATA[Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731830</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731830-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Gastric-cancer-illustration.webp?t=1610744617" type="image/png" medium="image" fileSize="551352">
        <media:title type="plain">Gastric cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins </title>
      <description>
        <![CDATA[If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731829</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731829-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-compass.webp?t=1770672078" type="image/jpeg" medium="image" fileSize="512881">
        <media:title type="plain">China compass </media:title>
      </media:content>
    </item>
    <item>
      <title>GLP-1s and more weigh in at ADA</title>
      <description>
        <![CDATA[GLP-1 receptor agonists remained center stage at the 2026 Scientific Sessions of the American Diabetes Association with Boehringer Ingelheim GmbH and Astrazeneca plc, joining the leaders, Eli Lilly and Co. and Novo Nordisk A/S, in presenting data for their respective GLP-1 drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731706</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731706-glp-1s-and-more-weigh-in-at-ada</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Close-up-of-injector-pen-in-hands.webp?t=1736374814" type="image/jpeg" medium="image" fileSize="117912">
        <media:title type="plain">Close-up of injector pen in hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Clinical footwork pays off in Tango’s PDAC combo phase I/II</title>
      <description>
        <![CDATA[Tango Therapeutics Inc. will be sitting down with the U.S. FDA soon to discuss pivotal work ahead based on what Cantor analyst Eric Schmidt called “amazing” data from the phase I/II study of vopimetostat, a PRMT5 inhibitor, paired with Revolution Medicines Inc.’s RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) as well as non-small cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731691</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731691-clinical-footwork-pays-off-in-tangos-pdac-combo-phase-i-ii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Pancreatic-cancer-anatomy.webp?t=1780952171" type="image/jpeg" medium="image" fileSize="160961">
        <media:title type="plain">Pancreatic cancer anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins </title>
      <description>
        <![CDATA[If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731634</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731634-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-compass.webp?t=1770672078" type="image/jpeg" medium="image" fileSize="512881">
        <media:title type="plain">China compass </media:title>
      </media:content>
    </item>
    <item>
      <title>Roche develops PCR test to detect the Ebola Bundibugyo virus</title>
      <description>
        <![CDATA[Roche Holding AG has rapidly developed a research-use only molecular PCR test to detect the rare Ebola Bundibugyo virus, to support response efforts amid the ongoing outbreak in the Democratic Republic of Congo and Uganda. The test comes as commentary in <em>The Lancet</em> this week underscored the urgent need for a fit-for-purpose diagnostic test, as it warned that the absence of reliable testing is hampering efforts to ascertain the scale of the epidemic and understand the transmissibility of this strain of Bundibugyo virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731630</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731630-roche-develops-pcr-test-to-detect-the-ebola-bundibugyo-virus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Swab-sample-from-patient.webp?t=1780688817" type="image/jpeg" medium="image" fileSize="74251">
        <media:title type="plain">Swab sample and patient</media:title>
      </media:content>
    </item>
    <item>
      <title>Ona raises $86.6M series B for ADCs to treat advanced cancers</title>
      <description>
        <![CDATA[Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731620</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731620-ona-raises-866m-series-b-for-adcs-to-treat-advanced-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-dollar-sign.webp?t=1624487200" type="image/png" medium="image" fileSize="316216">
        <media:title type="plain">3D dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Autobahn on the fast track with bipolar thyroid agonist</title>
      <description>
        <![CDATA[Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous system thyroid hormone receptor agonist, or thyromimetic, is moving toward a registrational path and a clinical readout in major depressive disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731618</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731618-autobahn-on-the-fast-track-with-bipolar-thyroid-agonist</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Depression-and-medication.webp?t=1720465598" type="image/jpeg" medium="image" fileSize="70638">
        <media:title type="plain">Woman taking medication for mental illness</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent submits NDA for CLDN18.2 ADC for gastric cancer</title>
      <description>
        <![CDATA[Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731617</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731617-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Gastric-cancer-illustration.webp?t=1610744617" type="image/png" medium="image" fileSize="551352">
        <media:title type="plain">Gastric cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Zynlonta Lotis position in DLBCL strains ADC shares</title>
      <description>
        <![CDATA[ADC Therapeutics SA blamed patients’ advanced age on the death imbalance in the phase III Lotis-5 confirmatory trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Whatever the reason, Wall Street wasn’t pleased and shares (NYSE:ADCT) closed June 4 at $1.32, down 57%, or $1.77.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731616</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731616-zynlonta-lotis-position-in-dlbcl-strains-adc-shares</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Diffuse-large-B-cell-lymphoma---isometric-view.webp?t=1780608328" type="image/jpeg" medium="image" fileSize="141240">
        <media:title type="plain">Diffuse large B-cell lymphoma - isometric view</media:title>
      </media:content>
    </item>
    <item>
      <title>D&amp;D’s zabopegdutide shows more upbeat top-line phase II MASH data </title>
      <description>
        <![CDATA[D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731650</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731650-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-damage-fibrosis-cirrhosis.webp?t=1769528466" type="image/jpeg" medium="image" fileSize="677639">
        <media:title type="plain">Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis</media:title>
      </media:content>
    </item>
    <item>
      <title>Cancer specter looming, Abtect effect in UC wallops Abivax</title>
      <description>
        <![CDATA[Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up in phase III top-line data from the Abtect maintenance trial with obefazimod. Paris-based Abivax SA’s oral, first-in-class miRNA-124 enhancer performed well in adults with moderately to severely active ulcerative colitis (UC), but shares of (NASDAQ:ABVX) closed June 2 at $72.50, down 44%, or $57.19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731525</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731525-cancer-specter-looming-abtect-effect-in-uc-wallops-abivax</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Stomach-pain.webp?t=1745258577" type="image/jpeg" medium="image" fileSize="208753">
        <media:title type="plain">Person holding stomach in pain </media:title>
      </media:content>
    </item>
    <item>
      <title>ASCO 2026: Grail shifts focus to secondary endpoints in UK study</title>
      <description>
        <![CDATA[New data from Grail Inc.’s randomized study of its Galleri multicancer early detection test could not alter the fact that the U.K. trial missed the primary endpoint of reducing the number of cancers diagnosed at stage III and stage IV. But the company is now suggesting that discounting the initial screen, when most late stage cancers were detected, would be more representative of a real-life steady state screening program.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731515</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731515-asco-2026-grail-shifts-focus-to-secondary-endpoints-in-uk-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Grail-Galleri-multicancer-early-detection-test-2-20.webp?t=1771619968" type="image/jpeg" medium="image" fileSize="215805">
        <media:title type="plain">Grail Galleri multicancer early detection test </media:title>
        <media:description type="plain">Credit: Grail Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Phase II bid Turns out safe, EASI, effective; AD topical island?</title>
      <description>
        <![CDATA[Turn Therapeutics Inc. made public strongly positive findings from an interim analysis that involves the first 50 subjects in the ongoing phase II atopic dermatitis (AD) trial with IL-36 inhibitor GX-03.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731511</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731511-phase-ii-bid-turns-out-safe-easi-effective-ad-topical-island</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Hand-holding-elbow.webp?t=1686261133" type="image/jpeg" medium="image" fileSize="145830">
        <media:title type="plain">Hand holding elbow</media:title>
      </media:content>
    </item>
    <item>
      <title>Oculis shifts focus after phase III DME disappointment</title>
      <description>
        <![CDATA[The much-awaited phase III readout from Oculis Holding AG’s OCS-01 in diabetic macular edema (DME) fell short of expectations, delaying the possibility of a topical eye drop option for DME patients and prompting the company to shuffle its pipeline priorities, with a focus on late-stage programs targeting optic neuropathies and dry eye disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731510</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731510-oculis-shifts-focus-after-phase-iii-dme-disappointment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eyedrops.webp?t=1620150844" type="image/png" medium="image" fileSize="518130">
        <media:title type="plain">Woman using eyedrops</media:title>
      </media:content>
    </item>
    <item>
      <title>Daraxonrasib, emactuzumab headline April's phase III cancer wins</title>
      <description>
        <![CDATA[<em>BioWorld</em> tracked 143 clinical trial readouts across phases I through III in April 2026, down from 209 in March, but roughly in line with 152 in February and 144 in January. By phase, April’s readouts included 47 from phase I, 59 from phase II and 37 in phase III. Among phase III programs, 15 trials reported positive results and two failed to meet primary endpoints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731456</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731456-daraxonrasib-emactuzumab-headline-aprils-phase-iii-cancer-wins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Doctor-patient-consultation.webp?t=1763072167" type="image/jpeg" medium="image" fileSize="407532">
        <media:title type="plain">Doctor-patient consultation</media:title>
      </media:content>
    </item>
    <item>
      <title>WHO selects vaccines, therapeutics for Ebola outbreak field trials</title>
      <description>
        <![CDATA[“I need to be honest with you about something important. Most previous Ebola outbreaks in the Democratic Republic of Congo (DRC) were caused by a virus called Ebola Zaire, for which we have vaccines and treatments. This outbreak is caused by a different virus called Ebola Bundibugyo. There are currently no approved vaccines or treatments for it.” This was the stark message from Tedros Adhanom Ghebreyesus, director general of the World Health Organization (WHO) in an open letter to the people of the DRC, as he traveled to the country on Friday, May 29.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731455</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731455-who-selects-vaccines-therapeutics-for-ebola-outbreak-field-trials</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Vials-syringes-pills-and-masks.webp?t=1637267696" type="image/png" medium="image" fileSize="488812">
        <media:title type="plain">Vials, syringes, pills and masks</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS’ mezigdomide doubles PFS in multiple myeloma</title>
      <description>
        <![CDATA[Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma was successful. Nearly three months later, the magnitude of success for its Pomalyst (pomalidomide) successor is clear.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731454</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731454-bms-mezigdomide-doubles-pfs-in-multiple-myeloma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Multiple-myeloma---healthy-and-cancerous-bone-marrow.webp?t=1780089558" type="image/jpeg" medium="image" fileSize="209895">
        <media:title type="plain">Healthy (left) vs. cancerous bone marrow</media:title>
      </media:content>
    </item>
    <item>
      <title>Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections</title>
      <description>
        <![CDATA[GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731439</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731439-breakthrough-as-gsks-bepirovirsen-clears-19-of-chronic-hep-b-infections</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Liver-with-hepatitis-viruses.webp?t=1779996120" type="image/jpeg" medium="image" fileSize="162084">
        <media:title type="plain">Liver with hepatitis viruses, blood cells</media:title>
      </media:content>
    </item>
    <item>
      <title>D&amp;D’s zabopegdutide shows more upbeat top-line phase II MASH data </title>
      <description>
        <![CDATA[D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731423</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731423-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-damage-fibrosis-cirrhosis.webp?t=1769528466" type="image/jpeg" medium="image" fileSize="677639">
        <media:title type="plain">Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis</media:title>
      </media:content>
    </item>
    <item>
      <title>Apogee orbiting big AD market as Apex phase II data land</title>
      <description>
        <![CDATA[Apogee Therapeutics Inc. loaded up on what could total as much as $1.3 billion in financial fuel from Blackstone Life Sciences funds that will be used to propel zumilokibart (zumi), which yielded positive phase II results in atopic dermatitis (AD). A phase III experiment with the anti-IL-13 antibody is planned for the second half of this year, pending talks with regulators.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731418</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731418-apogee-orbiting-big-ad-market-as-apex-phase-ii-data-land</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Close-up-dermatitis-on-the-skin.webp?t=1754678599" type="image/jpeg" medium="image" fileSize="193819">
        <media:title type="plain">Close up dermatitis on the skin</media:title>
      </media:content>
    </item>
    <item>
      <title>Work underway on vaccines, antivirals against rare Bundibugyo Ebola outbreak</title>
      <description>
        <![CDATA[Less than two weeks after the outbreak was officially declared, animal studies of a newly designed vaccine against the Bundibugyo Ebola virus are now underway in the U.S. and U.K., and the Serum Institute of India is standing ready to manufacture the vaccine for clinical trials. If the animal tests are positive, the vaccine will be ready for clinical trials in two to three months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731403</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731403-work-underway-on-vaccines-antivirals-against-rare-bundibugyo-ebola-outbreak</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Ebola-virus-research.webp?t=1779828015" type="image/jpeg" medium="image" fileSize="128796">
        <media:title type="plain">Ebola virus in petri dish with lab, scientist background</media:title>
      </media:content>
    </item>
    <item>
      <title>Lilly buys three vaccine makers; PCSK9 base editor shows promise</title>
      <description>
        <![CDATA[As the most active biopharma acquirer of 2026, Eli Lilly and Co. offered to buy three vaccine companies for up to $3.8 billion combined, while it simultaneously released positive early clinical results of a gene editing medicine brought into the fold last year through its buyout of Verve Therapeutics Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731401</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731401-lilly-buys-three-vaccine-makers-pcsk9-base-editor-shows-promise</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Syringes-in-virus-cell-company-logos.webp?t=1779831670" type="image/png" medium="image" fileSize="273178">
        <media:title type="plain">Syringes in virus cell; Lilly, Curevo, Limmatech, Vaccine Company   logos</media:title>
      </media:content>
    </item>
    <item>
      <title>MEK inhibitor delivers 17.3-month OS for pancreatic cancer </title>
      <description>
        <![CDATA[Immuneering Corp. reported a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients treated with its MEK inhibitor atebimetinib (IMM-1-104) plus modified gemcitabine/nab-paclitaxel in a phase IIa trial. Mizuho analyst Graig Suvannavejh called the results “astounding … easily beating current standard-of-care treatments.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/731386</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731386-mek-inhibitor-delivers-173-month-os-for-pancreatic-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/pancreatic-cancer-pancreas-3D.webp?t=1729610305" type="image/jpeg" medium="image" fileSize="283423">
        <media:title type="plain">Illustration of cancer in the pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Infex has positive phase IIa data in bronchiectasis; preps for next trial </title>
      <description>
        <![CDATA[Infex Therapeutics Ltd. has published positive phase IIa data for its lead program, RESP-X, in the treatment of exacerbations of chronic respiratory infections caused by <em>Pseudomonas aeruginosa</em> and is now laying the ground for phase IIb development, after raising £4.3 million (US$5.8 million) in new capital.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731376</guid>
      <pubDate>Thu, 21 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731376-infex-has-positive-phase-iia-data-in-bronchiectasis-preps-for-next-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-and-Pseudomonas-aeruginosa.webp?t=1779387668" type="image/jpeg" medium="image" fileSize="260481">
        <media:title type="plain">Lung infection caused by bacteria Pseudomonas aeruginosa</media:title>
      </media:content>
    </item>
    <item>
      <title>Another Triumph: Lilly’s triple G agonist scores in obesity </title>
      <description>
        <![CDATA[Posting another win for its triple G agonist, Eli Lilly and Co. rolled out top-line phase III data from Triumph-1 showing that all doses of retatrutide met primary and key secondary endpoints for obesity, with participants losing on average between 19% and 28.3% of body weight and significantly improving their cardiovascular risk factors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731371</guid>
      <pubDate>Thu, 21 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731371-another-triumph-lillys-triple-g-agonist-scores-in-obesity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Feet-on-scale-and-measuring-tape.webp?t=1709071824" type="image/jpeg" medium="image" fileSize="141907">
        <media:title type="plain">Feet on scale and measuring tape</media:title>
      </media:content>
    </item>
    <item>
      <title>Subgroup analysis of the Champion-AF trial shows age not a factor</title>
      <description>
        <![CDATA[A subgroup analysis of data from Boston Scientific Corp.’s Champion-AF trial, which looked at the outcomes for patients with atrial fibrillation treated with a left atrial appendage closure (LAAC) device compared to direct oral anticoagulants (DOACs), found that the efficacy and safety of LAAC compared to DOAC are not affected by age. The data were presented at the EuroPCR conference in Paris.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731344</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731344-subgroup-analysis-of-the-champion-af-trial-shows-age-not-a-factor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Boston-Scientific-Watchman-FLX-.webp?t=1779309137" type="image/jpeg" medium="image" fileSize="104199">
        <media:title type="plain">Boston Scientific Watchman FLX</media:title>
        <media:description type="plain">Watchman FLX left atrial appendage closure device. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>All Women data show Allegra edge in female TAVR patients</title>
      <description>
        <![CDATA[Data from the All Women clinical trial, which looked at the Allegra transcatheter aortic valve replacement (TAVR) system compared to balloon-expandable valves (BEV) in women with aortic stenosis, showed that Allegra delivered lower mean gradients and less prosthesis-patient mismatch than BEVs. The data presented at the EuroPCR conference in Paris was the first randomized head-to-head comparison of different TAVR platforms conducted exclusively in women.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731340</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731340-all-women-data-show-allegra-edge-in-female-tavr-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Biosensors-International-Allegra-transcatheter-heart-valve-5-20.webp?t=1779308345" type="image/jpeg" medium="image" fileSize="73313">
        <media:title type="plain">Biosensors International Allegra transcatheter heart valve</media:title>
        <media:description type="plain">Allegra transcatheter heart valve. Credit: Biosensors International </media:description>
      </media:content>
    </item>
    <item>
      <title>Immunovant rises on IMVT-1402 data in difficult-to-treat RA</title>
      <description>
        <![CDATA[Shares of Immunovant Inc. (NASDAQ:IMVT) gained 35% after the firm disclosed early but “compelling” data from a phase IIb study testing next-generation FcRn inhibitor IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA), including those whose disease has persisted despite treatment with TNF and JAK inhibitors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731339</guid>
      <pubDate>Wed, 20 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731339-immunovant-rises-on-imvt-1402-data-in-difficult-to-treat-ra</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Inflammatory/Hands-with-joint-pain.webp?t=1779310991" type="image/jpeg" medium="image" fileSize="139608">
        <media:title type="plain">Hands highlighted with joint pain</media:title>
      </media:content>
    </item>
  </channel>
</rss>
